Recurrent Laryngeal Squamous Cell Carcinoma Clinical Trial
Official title:
Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II
This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back. Interstitial photodynamic therapy uses a combination of laser light and a light-sensitive drug called porfimer sodium to destroy tumors. During treatment a laser light is used to activate the drug. Interstitial photodynamic therapy may be an effective treatment for head and neck cancer.
PRIMARY OBJECTIVES:
I. Demonstrate that our image-guided interstitial photodynamic therapy (I-PDT) dosimetry
system can be used to tailor this therapy to individual patients.
OUTLINE:
Patients receive porfimer sodium intravenously (IV) over 3-5 minutes on day 0. Patients then
undergo image-guided I-PDT on day 2.
After completion of study, patients are followed up at 1 month, 2 months, 4 months, and then
every 2 months for up to 12 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03468218 -
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
|
Phase 2 | |
Recruiting |
NCT04862650 -
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Completed |
NCT01256385 -
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
|
Phase 2 | |
Completed |
NCT03032250 -
Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer
|
N/A | |
Recruiting |
NCT04754321 -
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
|
Phase 1 | |
Terminated |
NCT02388932 -
Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer
|
N/A | |
Terminated |
NCT02196168 -
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05063552 -
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
|
Phase 2/Phase 3 | |
Recruiting |
NCT04588038 -
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
|
Phase 1 | |
Active, not recruiting |
NCT04576091 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
|
Phase 1 | |
Recruiting |
NCT05172258 -
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT02007200 -
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
|
Phase 2 | |
Completed |
NCT01064479 -
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Completed |
NCT00458978 -
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT01254617 -
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01267240 -
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00588770 -
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT04671667 -
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT00494182 -
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
|
Phase 2 |